Promed Of India To Spend $27.5 Million Expanding Next Three Years
This article was originally published in PharmAsia News
Executive Summary
India's Promed Group says it plans to make a large investment over the next three years to expand its overseas market and the capacity to deal with it. President Deepak Bahri said at a news conference the company plans to pour $27.5 million into the expansion, nearly half of it to double the capacity of one of its production plants. Other plants would be built in developed countries if the firm gets approvals from regulators, he said. Bahri said Promed expects to get European Union clearance for his plant yet this year and U.S. FDA approval next year. Promed plans to introduce as many as a dozen generics a year. (Click here for more
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.